2-[(2,5-dimethylpyrrol-1-yl)]-4-methylpyrimidine | 474522-99-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[(2,5-dimethylpyrrol-1-yl)]-4-methylpyrimidine
• 英文别名: 2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyrimidine；2-(2,5-dimethylpyrrol-1-yl)-4-methylpyrimidine
• CAS: 474522-99-1
• 化学式: C₁₁H₁₃N₃
• 分子量: 187.244
• InChiKey: AAXJTEKZTPUJDI-UHFFFAOYSA-N

物化性质

• 沸点：
  364.3±50.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[(2,5-dimethylpyrrol-1-yl)]-4-methylpyrimidine 、 Bredereck 试剂 反应 0.75h， 生成
  参考文献：
  名称：

  PYRIMIDINYLISOXAZOLE DERIVATIVE

  摘要：

  公开号：

  EP1832584B1
• 作为产物：
  描述：

  2-氨基-4-甲基嘧啶 、 2,5-己二酮 反应 11.0h， 以40%的产率得到2-[(2,5-dimethylpyrrol-1-yl)]-4-methylpyrimidine
  参考文献：
  名称：

  PYRIMIDINYLISOXAZOLE DERIVATIVE

  摘要：

  公开号：

  EP1832584B1

文献信息

• Heterocyclic amide compounds as apolipoprotein b inhibitors
  申请人：Takasugi Hisashi

  公开号：US20050038035A1

  公开（公告）日：2005-02-17

  The present invention relates to a compound of the formula (I) wherein R 1 is optionally substituted aryl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A 1 ) m1 -(A 2 ) m2 -; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及一种化合物，其分子式为（I），其中R1为可选取代芳基；R2为可选取代芳基、可选取代杂环芳基、可选取代较低环烷基、可选取代芳氧基、可选取代芳基磺酰基、乙烯基、氨基甲酰基、保护羧基或保护氨基；环A为由可选取代芳基或可选取代杂环芳基衍生的二价残基；X为由环烷烯、萘、不饱和的5或6元杂单环基衍生的二价残基，每种残基均可选取代，以及取代苯基；Y为-(A1)m1-(A2)m2-；Z为直接键或哌嗪，或其盐。本发明的化合物及其盐能抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于高循环Apo B水平引起的疾病或病症的药物。
• Amide compounds
  申请人：——

  公开号：US20040157866A1

  公开（公告）日：2004-08-12

  The present invention relates to compounds of the formula (I) wherein X 1 is wherein R 1 , R 2 and R 10 are independently hydrogen or a suitable substituent; R 11 and R 12 are independently hydrogen or a suitable substituent; R is unsaturated 5 to 6-membered heteromonocyclic group; A is direct bond or —NH—; X 2 is monocyclic arylene, unsaturated 5 to 6-membered heteromonocyclic group or cycloalkenylene; Y is bivalent group selected from ethylene, trimethylene and vinylene, wherein CH 2 is optionally replaced by NH or O, and CH is optionally replaced by N; and Z is —(CH 2 ) n —, —CO—(CH 2 ) m —, —CH═CH— or —CO—NH—, wherein n is 1, 2 or 3 and m is 1 or 2, or a salt thereof. The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B. 1

  本发明涉及公式（I）的化合物，其中X1为R1，R2和R10分别为氢原子或适当的取代基；R11和R12分别为氢原子或适当的取代基；R为不饱和的5至6元杂环单环基；A为直接键或—NH—；X2为单环芳烃，不饱和的5至6元杂环单环基或环烯基；Y为乙烯基，三亚甲基或乙烯基中选择的双价基团，其中CH2可以被NH或O替代，CH可以被N替代；Z为—（ ）n—，—CO—（ ）m—，—CH=CH—或—CO—NH—，其中n为1、2或3，m为1或2，或其盐。本发明的化合物抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于Apo B循环水平升高而导致的疾病或病症的药物。
• Pyrimidinylisoxazole Derivatives
  申请人：Hasumi Koichi

  公开号：US20080114003A1

  公开（公告）日：2008-05-15

  The invention discloses isoxazole derivatives represented by a formula, in which R 1 stands for hydrogen, lower alkyl, amino, halogen, lower alkoxy and the like, R 2 stands for substituted or unsubstituted aryl and the like, R 3 stands for hydrogen or lower alkyl, R 4 stands for substituted or unsubstituted phenyl and the like, and Y stands for —CH 2 —, —CO—, —CH(CH 3 )—, —O—, —NH— and the like, or pharmaceutically acceptable salts thereof, which have excellent p38MAPkinase inhibitory action.

  本发明揭示了由式子表示的异唑啉衍生物，其中R1代表氢、低碳基、氨基、卤素、低烷氧基等；R2代表取代或未取代的芳基等；R3代表氢或低碳基；R4代表取代或未取代的苯基等；Y代表—CH2—、—CO—、—CH(CH3)—、—O—、—NH—等，或其药学上可接受的盐，具有出色的p38MAPkinase抑制作用。
• PYRIMIDINYLISOXAZOL DERIVATIVE
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP1832584A1

  公开（公告）日：2007-09-12

  The invention discloses isoxazole derivatives represented by a formula, in which R1 stands for hydrogen, lower alkyl, amino, halogen, lower alkoxy and the like, R2 stands for substituted or unsubstituted aryl and the like, R3 stands for hydrogen or lower alkyl, R4 stands for substituted or unsubstituted phenyl and the like, and Y stands for -CH2, -CO-, -CH(CH3)-, -O-, -NH- and the like, or pharmaceutically acceptable salts thereof, which have excellent p38MAPkinase inhibitory action.

  本发明公开了由式表示的异噁唑衍生物，其中 R1 代表氢、低级烷基、氨基、卤素、低级烷氧基等，R2 代表取代或未取代的芳基等，R3 代表氢或低级烷基，R4 代表取代或未取代的苯基等，Y 代表-CH2、-CO-、-CH(CH3)-、-O-、-NH-等，或其药学上可接受的盐，它们具有优异的 p38MAPkinase 抑制作用。
• BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1383760A1

  公开（公告）日：2004-01-28